Genetically Encoded FRET-Based Nanosensor for Real-Time Monitoring of A549 Exosomes: Early Diagnosis of Cancer
Analytical Chemistry · 04.04.2023 · 95 (13) · 5738-5746
DOI: 10.1021/acs.analchem.2c05774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 23.03.2023. Verfasst von Reshma Bano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India. Hauptthemen laut MEDLINE: Biosensing Techniques, Exosomes, Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Indian Council of Medical Research, University Grants Commission.
Abstract (Originalsprache)
Exosomes contain a plethora of unique disease biomarkers involving cellular homeostasis, infection dissemination, cancer development, and cardiac diseases. Exosomes originating from cancer cells have promising biomarkers for the early detection and assessment of the therapeutic response to cancer. The exosomal epidermal growth factor receptor (EGFR) is a potential biomarker which is overexpressed in cancer; thus, the level of EGFR expression is investigated by so many methods in a liquid and solid biopsy. The optimal method for isolating pure exosomal EGFRs has not been well understood so far. Current approaches are complicated and time-consuming, therefore hampering their clinical applications. Here, we demonstrate the creation of an innovative fluorescence resonance energy transfer (FRET) sensor, named ExoSen (exosome sensor), which can be implemented to determine the concentration of exosomal EGFRs at in vitro as well as in vivo levels. In this study, a sensing element for A549 exosomes, mitogen-inducible gene 6 (MIG6), has been employed between the FRET pair ECFP and Venus. MIG6 binding to ExoSen induced a conformational change that can be monitored by a variation in the FRET ratio. Moreover, the developed sensor, expressed in bacterial, yeast, and HEK-293T cells, demonstrates an increased FRET ratio with the addition of A549 exosomes, which can quantify the A549 exosomes noninvasively. The ExoSen enables rapid detection of A549 exosomes with great sensitivity at a concentration of 3.5 × 109 particles/mL. ExoSen is stable to pH fluctuations and provides a highly accurate, real-time optical readout in cell-based experiments by using confocal microscopy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India.
ORCID-Profile: Mohd Mohsin
Förderung
- Indian Council of Medical Research
- University Grants Commission
Zitieren
APA
Bano, R., Soleja, N., & Mohsin, M. (2023). Genetically Encoded FRET-Based Nanosensor for Real-Time Monitoring of A549 Exosomes: Early Diagnosis of Cancer. Analytical Chemistry, 95(13), 5738-5746. https://doi.org/10.1021/acs.analchem.2c05774
Vancouver
Bano R, Soleja N, Mohsin M. Genetically Encoded FRET-Based Nanosensor for Real-Time Monitoring of A549 Exosomes: Early Diagnosis of Cancer. Analytical Chemistry. 2023;95(13):5738-5746. doi:10.1021/acs.analchem.2c05774
BibTeX
@article{Bano2023,
author = {Bano, Reshma and Soleja, Neha and Mohsin, Mohd},
title = {Genetically Encoded FRET-Based Nanosensor for Real-Time Monitoring of A549 Exosomes: Early Diagnosis of Cancer},
journal = {Analytical Chemistry},
year = {2023},
volume = {95},
number = {13},
pages = {5738--5746},
doi = {10.1021/acs.analchem.2c05774}
}
EUVIMED